Now through April is an exciting but nerve-racking time for high school seniors and their parents receiving decisions from colleges about admission and financial aid applications.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...